Do analysts rate UGRO or MWG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score urban-gro 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Multi Ways 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, UGRO or MWG?

Multi Ways has higher revenue and earnings than urban-gro. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio urban-gro $17.40M 0.11 -$22.10M -$27.87 N/A Multi Ways $44.77M 0.13 $1.79M N/A N/A

Is UGRO or MWG more profitable?

Multi Ways has a net margin of 0.00% compared to urban-gro's net margin of -82.11%. Multi Ways' return on equity of 0.00% beat urban-gro's return on equity. Company Net Margins Return on Equity Return on Assets urban-gro -82.11% -118.44% -33.76% Multi Ways N/A N/A N/A

Do analysts recommend UGRO or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score urban-gro 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend UGRO or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score urban-gro 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BGLC or UGRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNexus Gene Lab 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 urban-gro 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BGLC or UGRO more profitable?

BioNexus Gene Lab has a net margin of -54.70% compared to urban-gro's net margin of -82.11%. BioNexus Gene Lab's return on equity of -37.43% beat urban-gro's return on equity. Company Net Margins Return on Equity Return on Assets BioNexus Gene Lab -54.70% -37.43% -32.88% urban-gro -82.11% -118.44% -33.76%

Do analysts prefer GSL-B or UGRO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Global Ship Lease Representing 8.75 Cumulative Redeemable 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 urban-gro 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, GSL-B or UGRO?

Global Ship Lease Representing 8.75 Cumulative Redeemable has higher earnings, but lower revenue than urban-gro. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Global Ship Lease Representing 8.75 Cumulative Redeemable N/A N/A N/A N/A N/A urban-gro $17.40M 0.11 -$22.10M -$27.87 N/A

urban-gro (UGRO) Competitors

$1.47 +0.29 (+24.58%)

As of 08/5/2026

Compare

UGRO vs. MWG, BGMS, CAPS, BGLC, and GSL-B

Should you buy urban-gro stock or one of its competitors? MarketBeat compares urban-gro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with urban-gro include Multi Ways (MWG), Cyclacel Pharmaceuticals (BGMS), Capstone Therapeutics (CAPS), BioNexus Gene Lab (BGLC), and Global Ship Lease Representing 8.75 Cumulative Redeemable (GSL-B). These companies are all part of the "trading companies & distributors" industry.

How does urban-gro compare to Multi Ways?

urban-gro (NASDAQ:UGRO) and Multi Ways (NYSE:MWG) are both small-cap industrials companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

20.6% of urban-gro shares are held by institutional investors. Comparatively, 0.8% of Multi Ways shares are held by institutional investors. 4.4% of urban-gro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
urban-gro	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Multi Ways	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Multi Ways has a net margin of 0.00% compared to urban-gro's net margin of -82.11%. Multi Ways' return on equity of 0.00% beat urban-gro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
urban-gro	-82.11%	-118.44%	-33.76%
Multi Ways	N/A	N/A	N/A

In the previous week, urban-gro's average media sentiment score of 0.00 equaled Multi Ways'average media sentiment score.

Company	Overall Sentiment
urban-gro	Neutral
Multi Ways	Neutral

Multi Ways has higher revenue and earnings than urban-gro.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
urban-gro	$17.40M	0.11	-$22.10M	-$27.87	N/A
Multi Ways	$44.77M	0.13	$1.79M	N/A	N/A

urban-gro has a beta of -2.91, suggesting that its stock price is 391% less volatile than the broader market. Comparatively, Multi Ways has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Summary

Multi Ways beats urban-gro on 7 of the 10 factors compared between the two stocks.

How does urban-gro compare to Cyclacel Pharmaceuticals?

urban-gro (NASDAQ:UGRO) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
urban-gro	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.6% of urban-gro shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 4.4% of urban-gro shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

urban-gro has a beta of -2.91, meaning that its stock price is 391% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market.

In the previous week, urban-gro's average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
urban-gro	Neutral
Cyclacel Pharmaceuticals	Neutral

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to urban-gro's net margin of -82.11%. Cyclacel Pharmaceuticals' return on equity of -51.21% beat urban-gro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
urban-gro	-82.11%	-118.44%	-33.76%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than urban-gro. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than urban-gro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
urban-gro	$17.40M	0.11	-$22.10M	-$27.87	N/A
Cyclacel Pharmaceuticals	$750K	7.14	-$3M	-$4.54	N/A

Summary

Cyclacel Pharmaceuticals beats urban-gro on 8 of the 11 factors compared between the two stocks.

How does urban-gro compare to Capstone Therapeutics?

urban-gro (NASDAQ:UGRO) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

20.6% of urban-gro shares are held by institutional investors. Comparatively, 2.6% of Capstone Therapeutics shares are held by institutional investors. 4.4% of urban-gro shares are held by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Capstone Therapeutics had 1 more articles in the media than urban-gro. MarketBeat recorded 1 mentions for Capstone Therapeutics and 0 mentions for urban-gro. urban-gro's average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company	Overall Sentiment
urban-gro	Neutral
Capstone Therapeutics	Neutral

Capstone Therapeutics has higher revenue and earnings than urban-gro. Capstone Therapeutics is trading at a lower price-to-earnings ratio than urban-gro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
urban-gro	$17.40M	0.11	-$22.10M	-$27.87	N/A
Capstone Therapeutics	$48.11M	0.09	-$21.23M	-$3.37	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
urban-gro	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Capstone Therapeutics has a net margin of -41.26% compared to urban-gro's net margin of -82.11%. Capstone Therapeutics' return on equity of -114.15% beat urban-gro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
urban-gro	-82.11%	-118.44%	-33.76%
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

urban-gro has a beta of -2.91, meaning that its stock price is 391% less volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.52, meaning that its stock price is 252% less volatile than the broader market.

Summary

Capstone Therapeutics beats urban-gro on 8 of the 12 factors compared between the two stocks.

How does urban-gro compare to BioNexus Gene Lab?

BioNexus Gene Lab (NASDAQ:BGLC) and urban-gro (NASDAQ:UGRO) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNexus Gene Lab	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
urban-gro	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioNexus Gene Lab's average media sentiment score of 0.00 equaled urban-gro'saverage media sentiment score.

Company	Overall Sentiment
BioNexus Gene Lab	Neutral
urban-gro	Neutral

18.9% of BioNexus Gene Lab shares are held by institutional investors. Comparatively, 20.6% of urban-gro shares are held by institutional investors. 0.1% of BioNexus Gene Lab shares are held by company insiders. Comparatively, 4.4% of urban-gro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioNexus Gene Lab has a beta of 4.16, indicating that its share price is 316% more volatile than the broader market. Comparatively, urban-gro has a beta of -2.91, indicating that its share price is 391% less volatile than the broader market.

BioNexus Gene Lab has a net margin of -54.70% compared to urban-gro's net margin of -82.11%. BioNexus Gene Lab's return on equity of -37.43% beat urban-gro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%
urban-gro	-82.11%	-118.44%	-33.76%

BioNexus Gene Lab has higher earnings, but lower revenue than urban-gro. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than urban-gro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNexus Gene Lab	$7.43M	0.51	-$2.98M	-$1.48	N/A
urban-gro	$17.40M	0.11	-$22.10M	-$27.87	N/A

Summary

BioNexus Gene Lab beats urban-gro on 7 of the 11 factors compared between the two stocks.

How does urban-gro compare to Global Ship Lease Representing 8.75 Cumulative Redeemable?

Global Ship Lease Representing 8.75 Cumulative Redeemable (NYSE:GSL-B) and urban-gro (NASDAQ:UGRO) are both industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Global Ship Lease Representing 8.75 Cumulative Redeemable has higher earnings, but lower revenue than urban-gro.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Ship Lease Representing 8.75 Cumulative Redeemable	N/A	N/A	N/A	N/A	N/A
urban-gro	$17.40M	0.11	-$22.10M	-$27.87	N/A

In the previous week, Global Ship Lease Representing 8.75 Cumulative Redeemable's average media sentiment score of 0.00 equaled urban-gro'saverage media sentiment score.

Company	Overall Sentiment
Global Ship Lease Representing 8.75 Cumulative Redeemable	Neutral
urban-gro	Neutral

20.6% of urban-gro shares are owned by institutional investors. 4.4% of urban-gro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Global Ship Lease Representing 8.75 Cumulative Redeemable has a net margin of 0.00% compared to urban-gro's net margin of -82.11%. Global Ship Lease Representing 8.75 Cumulative Redeemable's return on equity of 0.00% beat urban-gro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Global Ship Lease Representing 8.75 Cumulative Redeemable	N/A	N/A	N/A
urban-gro	-82.11%	-118.44%	-33.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Ship Lease Representing 8.75 Cumulative Redeemable	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
urban-gro	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

urban-gro beats Global Ship Lease Representing 8.75 Cumulative Redeemable on 4 of the 7 factors compared between the two stocks.

Get urban-gro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UGRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UGRO vs. The Competition

Export

Metric	urban-gro	Trading Companies & Distributors Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$1.94M	$9.51B	$10.83B	$12.87B
Dividend Yield	N/A	3.40%	120.63%	9.93%
P/E Ratio	-0.05	30.52	28.36	25.30
Price / Sales	0.11	23.58	317.83	106.23
Price / Cash	N/A	48.38	24.91	50.37
Price / Book	-0.02	3.69	4.51	6.13
Net Income	-$22.10M	$373.80M	$607.47M	$342.95M
7 Day Performance	21.49%	3.63%	2.89%	3.19%
1 Month Performance	-16.95%	3.55%	0.48%	-1.98%
1 Year Performance	-83.76%	9.65%	13.75%	21.11%

urban-gro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UGRO urban-gro	N/A	$1.47 +24.6%	N/A	-85.4%	$1.94M	$17.40M	N/A	100	High Trading Volume
MWG Multi Ways	N/A	$1.15 +0.9%	N/A	-55.3%	$5.90M	$44.77M	N/A	92	Gap Up
BGMS Cyclacel Pharmaceuticals	0.6486 of 5 stars	$0.98 +11.4%	N/A	N/A	$4.86M	$750K	N/A	14	Gap Up High Trading Volume
CAPS Capstone Therapeutics	0.3108 of 5 stars	$0.26 +3.1%	N/A	-80.1%	$3.82M	$48.11M	N/A	38	News Coverage Upcoming Earnings Gap Up
BGLC BioNexus Gene Lab	0.7499 of 5 stars	$1.54 +7.7%	N/A	-72.1%	$3.46M	$7.43M	N/A	30	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UGRO) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

urban-gro (UGRO) Competitors

UGRO vs. MWG, BGMS, CAPS, BGLC, and GSL-B

How does urban-gro compare to Multi Ways?

Summary

How does urban-gro compare to Cyclacel Pharmaceuticals?

Summary

How does urban-gro compare to Capstone Therapeutics?

Summary

How does urban-gro compare to BioNexus Gene Lab?

Summary

How does urban-gro compare to Global Ship Lease Representing 8.75 Cumulative Redeemable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UGRO vs. The Competition

urban-gro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

urban-gro (UGRO) Competitors

UGRO vs. MWG, BGMS, CAPS, BGLC, and GSL-B

How does urban-gro compare to Multi Ways?

Do insiders and institutionals hold more shares of UGRO or MWG?

Do analysts rate UGRO or MWG?

Is UGRO or MWG more profitable?

Does the media prefer UGRO or MWG?

Which has higher valuation and earnings, UGRO or MWG?

Which has more risk and volatility, UGRO or MWG?

Summary

How does urban-gro compare to Cyclacel Pharmaceuticals?

Do analysts recommend UGRO or BGMS?

Do insiders & institutionals hold more shares of UGRO or BGMS?

Which has more volatility & risk, UGRO or BGMS?

Does the media refer more to UGRO or BGMS?

Is UGRO or BGMS more profitable?

Which has preferable earnings and valuation, UGRO or BGMS?

Summary

How does urban-gro compare to Capstone Therapeutics?

Do institutionals and insiders hold more shares of UGRO or CAPS?

Does the media refer more to UGRO or CAPS?

Which has stronger valuation and earnings, UGRO or CAPS?

Do analysts recommend UGRO or CAPS?

Is UGRO or CAPS more profitable?

Which has more volatility and risk, UGRO or CAPS?

Summary

How does urban-gro compare to BioNexus Gene Lab?

Do analysts prefer BGLC or UGRO?

Does the media favor BGLC or UGRO?

Do institutionals & insiders hold more shares of BGLC or UGRO?

Which has more volatility and risk, BGLC or UGRO?

Is BGLC or UGRO more profitable?

Which has preferable earnings and valuation, BGLC or UGRO?

Summary

How does urban-gro compare to Global Ship Lease Representing 8.75 Cumulative Redeemable?

Which has preferable earnings and valuation, GSL-B or UGRO?

Does the media prefer GSL-B or UGRO?

Do institutionals and insiders have more ownership in GSL-B or UGRO?

Is GSL-B or UGRO more profitable?

Do analysts prefer GSL-B or UGRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UGRO vs. The Competition

urban-gro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools